|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.77 USD | -2.65% |
|
+1.35% | +26.67% |
| 27/05 | Argus Raises Viatris Price Target to $18 From $15 | MT |
| 19/05 | Barclays Adjusts Price Target on Viatris to $22 From $17, Maintains Overweight Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.84TCr | |||||
| 1,01300Cr | |||||
| 57TCr | |||||
| 40TCr | |||||
| 32TCr | |||||
| 28TCr |
- Stock Market
- Stocks
- VTRS Stock
- Charts Viatris Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition